CMS Announces Delay To Rural DME Fee Schedule Changes
Executive Summary
A 2018 interim rule won’t be finalized for another year so regulators have more time to review the proposal and related stakeholder comments.
You may also be interested in...
Mr. Freeze: Biden’s Swift Move To Pause Last-Minute Trump-Era Regs
A raft of rules that affect the medtech industry are on ice for the time being while the new Biden administration determines whether the regulations should move forward. This and other stories topped our list of most-read Medtech Insight articles in January.
‘Core Pillars’ Of Safety And Innovation Take Center Stage In FDA Reports
The US FDA has issued a pair of reports focused on device safety and innovation. The reports describe recent steps the agency has taken to improve in the two areas, and what it plans to do next.
Interview: Theradaptive To Enter Clinical Trial For Spinal Fusion Implant
Theradaptive, which makes a device-biologic combination product to help speed bone healing, recently got authorization to start human trials from the US FDA. Medtech Insight spoke to CEO Luis Alvarez about the company’s past, present and future.